Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

National ICD Registry: The 2008 annual report on the National ICD Registry, released by the Heart Rhythm Society and American College of Cardiology Foundation on Sept. 2, shows that total complications for new implantable cardioverter defibrillators decreased from 3.78% in 2006 to 3.01% in 2008. Primary prevention patients accounted for 78% of ICD implants. Of the patients receiving an ICD for primary prevention, 79% met the published professional guidelines. As of June, the registry has collected data from 380,000 implants in the U.S., representing over 90% of all ICDs implanted in the U.S. from 1,432 participating hospitals and 4,563 participating physicians

You may also be interested in...



Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring

FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.

Edwards Looks To Smaller-Diameter Transcatheter Valve In 2010

Edwards Lifesciences hopes to overcome one of its biggest competitive disadvantages in the European transcatheter valve market early next year with the planned launch of a smaller-profile product

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel